PTTG/securin activates expression of p53 and modulates its function

Molecular Cancer

Volumn 3, Issue , 2004, Pages

  Hamid, Tariq ^a,b   Kakar, Sham S ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BAX; PROTEIN P53; SECURIN; TUMOR PROMOTER; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; PROTEIN BCL 2; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE C MYC; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; BREAST TUMOR; CELL LINE; CHEMISTRY; CYTOLOGY; GENETICS; KIDNEY; MALE; METABOLISM; ONCOGENE MYC; PHYSIOLOGY; PRENATAL DEVELOPMENT; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

MUS MUSCULUS;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; KIDNEY; MALE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 13644269946     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-3-18     Document Type: Article

References (43)

1. Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997, 11:433-441.
2. Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet 1999,84:211-216.
3. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999, 13:156-166.
4. Yu R, Melmed S: Oncogene activation in pituitary tumors. Brain Pathol 2001, 11:328-341.
5. Heaney AP, Nelson V, Fernando M, Horwitz G: Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab 2001, 86:5025-5032.
6. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S: Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000, 355:716-719.
7. Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett 2001, 163:131-139.
8. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M: PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004, 13:80-81.
9. Saez C, Pereda T, Borrero JJ, Espina A, Romero F, Tortolero M, Pintor-Toro JA, Segura DI, Japon MA: Expression of hPTTG protooncogene in lymphoid neoplasias. Oncogene 2002, 21: 173-8177.
10. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC, Franklyn JA: Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003, 88:2341-2347.
11. Saez C, Japon MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA: hPTTG is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 1999, 18:5473-5476.
12. Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Ishiguro H, Kudo J, Terashita Y, Konishi S, Fujii Y: Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 2002, 32:233-237.
13. Ramaswamy S, Ross KN, Lander ES, Goulb TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
14. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M: Cell cycle regulated expression and phosphorylation of hPTTG proto-oncogene product. Oncogene 2000, 19:403-409.
15. Yu R, Ren S-G, Horwitz GA, Wang Z, Melmed S: Pituitary Tumor Transforming Gene (PTTG) Regulates Placental JEG-3 Cell Division and Survival: Evidence from Live Cell Imaging. Mol Endocrinol 2000, 14:1137-146.
16. Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285: 18-422.
17. Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-Toro JA, Tortolero M: Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res 2001, 29:1300-1307.
18. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S: Human Pituitary Tumor-Transforming Gene Induces Angiogenesis. J Clin Endocrinol Metab 2001, 86:867-874.
19. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM: The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 2003, 148:203-211.
20. Pei L: Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function. J Biol Chem 2000, 275:31191-31198.
21. Pei L: Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 2001, 276: 484-8491.
22. Yu R, Lu W, Chen J, McCabe CJ, Medmed S: Overexpressed pituitary tumor transforming gene causes aneuploidy in live human cells. Endocrinology 2003, 144:4991-4998.
23. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA: Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002, 32:306-311.
24. Clem AL, Hamid T, Kakar SS: Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 2003, 322:113-121.
25. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X: DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 2003, 278:462-470.
26. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997, 57:1758-1768.
27. Tuck SP, Crawford L: Characterization of the human p53 gene promoter. Mol Cell Biol 1989, 9:2163-2172.
28. Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, Esche H: Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and myc/max. Oncogene 1999, 18:2728-2738.
29. Blackwood EM, Luscher B, Eisenman RN: myc and max associate in vivo. Genes Dev 1992, 6:71-80.
30. Cole MD, McMahon SB: The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999, 18:2916-2924.
31. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H: Oncogenic activity of the c-myc protein requires dimerization with max. Cell 1993, 72:233-245.
32. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312.
33. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC: A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003, 22:343-350.
34. Lu W, Pochampally R, Chen L, Traidej M, Wang Y, Chen J: Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene 2000, 19:232-240.
35. Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-171.
36. Martin LJ, Price AC, McClendon KB, Al-Abdulla NA, Subramaniam JR, Wong PC, Liu Z: Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins. J Neurochem 2003, 85:234-247.
37. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
38. Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA: hPTTG, a human homologue of rat PTTG, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 1998, 17:2187-2193.
39. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
40. Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G: c-myc functionally cooperates with bax to induce apoptosis. Mol Cell Biol 2002, 22:6158-6169.
41. Foletta VC: Transcription factor AP-1, and the role of Fra-2. Immunol Cell Biol 1996, 74:121-133.
42. Kakar SS, Chen L, Puri R, Flynn SE, Jennes L: Characterization of a polyclonal antibody to human pituitary tumor transforming gene 1 (PTTG1) protein. J Histochem Cytochem 2001, 49:1537-1546.
43. Panek RB, Lee YJ, Itoh-Lindstrom Y, Ting JP, Benveniste EN: Characterization of astrocyte nuclear proteins involved in IFNgamma-and TNF-alpha-mediated class II MHC gene expression. J Immunol 1994, 153:4555-4564.